Zhitong Finance App News, Goli Pharmaceutical-B (01672.HK) announced that ASC50 achieved positive results in a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical trial conducted by ASC50 in patients with mild to moderate plaque psoriasis in the US. This phase I study aimed to evaluate the safety, efficacy, and pharmacokinetics (NCT07024602) of 200 mg ASC50 once daily after 28 days of treatment in patients with mild to moderate plaque psoriasis.

Zhitongcaijing · 4d ago
Zhitong Finance App News, Goli Pharmaceutical-B (01672.HK) announced that ASC50 achieved positive results in a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical trial conducted by ASC50 in patients with mild to moderate plaque psoriasis in the US. This phase I study aimed to evaluate the safety, efficacy, and pharmacokinetics (NCT07024602) of 200 mg ASC50 once daily after 28 days of treatment in patients with mild to moderate plaque psoriasis.